QIAGEN has entered a partnership with pharmaceutical firm Eli Lilly and Company to develop a diagnostic tool for Alzheimer's disease.
The partnership expects to produce the first commercially available in-vitro diagnostic (IVD) panel for identifying APOE genetic variants, which have a role in the diagnosis of Alzheimer’s disease. Integrated with QIAGEN’s QIAstat-Dx platform, the IVD panel is claimed to be able to provide results within an hour to aid speedy treatment decisions.
Analyst Quick Take: In August 2024 , Qiagen also collaborated with pharmaceutical company AstraZeneca to develop companion diagnostics for the latter’s upcoming therapies for chronic diseases. QIAGEN will create and validate a genotyping assay using its QIAstat-Dx testing platform to detect and differentiate between multiple biomarkers, claiming to provide results within an hour.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.